Lexeo Therapeutics, Inc. Accounts Payable
Lexeo Therapeutics, Inc. (LXEO) had Accounts Payable of $4.18 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-12
- 2026-06-30: Accounts Payable, Current $4.18M.
- 2026-03-31: Accounts Payable, Current $3.33M.
- 2025-12-31: Accounts Payable, Current $4.86M.
- 2025-09-30: Accounts Payable, Current $4.66M.
| Period end | Accounts Payable, Current |
|---|---|
| 2026-06-30 | $4.18M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $3.33M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $4.86M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $4.66M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $20.02M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $11.98M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $6.42M 10-K · filed 2026-03-30 |
| 2024-09-30 | $8.44M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $5.76M 10-Q · filed 2024-08-12 |
| 2024-03-31 | $4.30M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $3.79M 10-K · filed 2025-03-24 |
| 2023-09-30 | $2.65M 10-Q · filed 2023-12-11 |
| 2022-12-31 | $2.68M 10-K · filed 2024-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |